Imara Inc. (IMRA) Tops Q1 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 7:00 AM EDTOn-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021
Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial
Higher dose arms open in both the Ardent and Forte Phase 2b clinical trials
Applications now being accepted for 2021 Real Impact grant program
Company to host conference call and live webcast today at 8:30 AM ET
BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq:... More
